Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2025 Jun 9:rs.3.rs-6683281.
doi: 10.21203/rs.3.rs-6683281/v1.

Factors associated with women's preference for an over-encapsulated Dual Prevention Pill: Findings from two clinical crossover trials among women in South Africa and Zimbabwe

Sanyukta Mathur  1 , Marlena Plagianos  1 , Barbara Friedland  1 , Irene Bruce  1 , Brady Burnett-Zieman  1 , Adlight Dandazi  2 , Petina Musara  2 , Nkosiphile Ndlovu  3 , Natasha Sedze  2 , Siyanda Tenza  3 , Krishnaveni Reddy  3 , Shile Zulu  3 , Lisa Haddad  1 , Caroline Murombedzi  2 , Nyaradzo Mgodi  2 , Thesla Palanee-Philips  3
Affiliations

Factors associated with women's preference for an over-encapsulated Dual Prevention Pill: Findings from two clinical crossover trials among women in South Africa and Zimbabwe

Sanyukta Mathur et al. Res Sq. .

Abstract

Background: A dual prevention pill (DPP) for co-delivery of pregnancy and HIV prevention is currently in development and will offer an alternative to taking two separate products. We examined behavioral, partnership/interpersonal, social, and structural correlates of preferences for an over-encapsulated DPP (as a proxy for the product in development, consisting of oral contraceptive pill and oral PrEP pill) among women and adolescent girls in South Africa and Zimbabwe to inform DPP introduction and counseling strategies.

Methods: This secondary analysis used data from two clinical crossover studies that compared the acceptability, adherence, and preference for the over-encapsulated DPP versus separate PrEP and oral contraceptives. HIV-uninfected, non-pregnant cisgender women were enrolled in Johannesburg, South Africa (n = 96, ages 18-40) and Harare, Zimbabwe (n = 30, ages 16-24). Participants were randomized 1:1 to use either DPP or two separate pills for three 28-day cycles, then switched. Preferences were measured at the end of crossover and via exit in-depth interviews.

Results: The mean age was 27 years in South Africa and 19 years for Zimbabwe. Most participants had completed secondary school. Childbearing was more common in Zimbabwe (97%) than South Africa (74%). Pregnancy prevention was highly valued in both sites (~ 90%), but Zimbabwean participants voiced greater concern about HIV. DPP preference was higher in Zimbabwe (62%) than South African (39%). In South Africa, DPP preference was associated with behavioral factors (anal sex, experience of sexual violence, relationship conflict, and transactional relationships/sex) and product characteristics (ease of use, side effects). In Zimbabwe, concern about HIV acquisition, interpersonal power, and structural factors (i.e., food insecurity and housing security) were associated with DPP preference. Qualitative interviews highlighted the DPP's simplicity as key advantage over two separate pills, though participants desired a smaller DPP and more discreet packaging to reduced stigma and ease use.

Conclusions: While women in both countries value integrated HIV and pregnancy prevention, distinct demographic, behavioral, and social factors influence DPP preference. Tailoring DPP introduction and support strategies to address specific challenges-such as relationship dynamics and product usability-may optimize the acceptance and effectiveness of dual prevention strategies.

Keywords: HIV prevention; South Africa; Zimbabwe; dual prevention; family planning; mixed-methods; multi-purpose prevention technologies; new technologies; preference; prevention.

PubMed Disclaimer

Conflict of interest statement

Competing interests. The authors declare that they have no competing interests Additional Declarations: No competing interests reported.

Figures

Figure 1
Figure 1
Images and dimensions of the co-formulated DPP regimen currently in development and the over-encapsulated DPP used in the studies
See this image and copyright information in PMC

References

    1. UNAIDS. Fact Sheet 2024 [Internet], Geneva: UNAIDS. 2024. [cited 2024 Nov 11]. Available from: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_...
    1. Bearak J, Popinchalk A, Ganatra B, Moller AB, Tunçalp Ö, Beavin C, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob Health. 2020;8(9):e1152–61. - PubMed
    1. Friedland BA, Plagianos M, Savel C, Kallianes V, Martinez C, Begg L, et al. Women Want Choices: Opinions from the Share.Learn.Shape Global Internet Survey About Multipurpose Prevention Technology (MPT) Products in Development. AIDS Behav. 2023;27(7):2190–204. - PMC - PubMed
    1. van der Straten A, Agot K, Ahmed K, et al. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018;21(3):e25094. - PMC - PubMed
    1. Minnis AM, Browne EN, Boeri M, Agot K, van der Straten A, Ahmed K et al. Young Women’s Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 1999. 2019;80(4):394–403. - PMC - PubMed

Publication types

LinkOut - more resources